VivoSeq
Other

Phase II Clinical Trial

0

Pipeline Programs↗

10

Active Trials↗

10

Companies Involved↗

Phase II Clinical Trial is an early-stage landscape with 0 programs across 10 companies. The most active players are Luye Pharma Group Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Shanghai Bao Pharmaceuticals Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.

0 programs

PreclinicalChia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

0 programs

PreclinicalS

Shanghai Bao Pharmaceuticals Co., Ltd.

0 programs

PreclinicalC

Chipscreen Biosciences, Ltd.

0 programs

PreclinicalS

Shanghai Reinovax Biologics Co.,LTD

0 programs

PreclinicalD

Dizal Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

32

clinical trials

Completed12 · 38%
Unknown status6 · 19%
Recruiting5 · 16%
Not yet recruiting3 · 9%
Terminated3 · 9%
Active, not recruiting2 · 6%
Other1 · 3%

Clinical Trials

Trial Activity

32 trials

Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns
Recruiting·SShanghai Bao Pharmaceuticals Co., Ltd.·Phase 2·NCT07025408·144 enrolled
A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
Recruiting·DDizal Pharmaceuticals·Phase 2·NCT06295432·90 enrolled
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
Recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT07252908·195 enrolled
Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Orthopedic Surgery
Recruiting·Luye Pharma Group Ltd. logoLuye Pharma Group Ltd.·Phase 2·NCT06467409·150 enrolled
Phase II Clinical Trial of Interleukin-2 in AD
Recruiting·TThe Methodist Hospital Research Institute·Phase 2·NCT06096090·40 enrolled
Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
Active, not recruiting·SShanghai Reinovax Biologics Co.,LTD·Phase 2·NCT06678620·992 enrolled
A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease
Active, not recruiting·KKissei Pharmaceutical Co., Ltd.·Phase 2·NCT06722729·150 enrolled
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Not yet recruiting·NNanjing Leads Biolabs Co.,Ltd·Phase 2·NCT07390383·110 enrolled
A Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of L2-01 in Subjects With Crohn's Disease
Not yet recruiting·LL2 Bio, LLC·Phase 2·NCT07010926·120 enrolled
Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial
Not yet recruiting·SSichuan Enray Pharmaceutical Sciences Company·Phase 2·NCT07491783·52 enrolled
A Phase II Clinical Trial of Chiglitazar for NASH
Completed·CChipscreen Biosciences, Ltd.·Phase 2·NCT05193916·104 enrolled
A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.
Completed·YYuhan Corporation·Phase 2·NCT02585596·275 enrolled
Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal Surgery
Completed·Luye Pharma Group Ltd. logoLuye Pharma Group Ltd.·Phase 2·NCT06204120·150 enrolled
Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC
Completed·—·Phase 2·NCT03573947·46 enrolled
HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00125970·480 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)